A Phase 2 Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib GS-0976 GS-9674 and Combinations in Subjects with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis

Brief description of study

This study is looking to enroll patients with liver fibrosis or cirrhosis as a result of nonalcoholic steatohepatitis (NASH). The purpose of this study is to see if the experimental drugs, Selonsertib (SEL), GS-0976, GS-9674, and combinations of these drugs are safe, well-tolerated, and whether they can reduce fibrosis (scar tissue) and the associated complications in subjects with fibrosis due to nonalcoholic steatohepatitis (NASH).


Clinical Study Identifier: s18-00168
ClinicalTrials.gov Identifier: NCTs18-00168


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.